To request a free sample copy of this report, please complete the form below.
What people say about us!

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

logos logos logos logos logos
Analyst Support
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.



Global Allergy Immunotherapy Market is segmented by Treatment, Allergy, Distribution Channel, and region. Based on Treatment, the market can be segmented into Subcutaneous Immunotherapy (SCIT), Sublingual Immunotherapy (SLIT) (Tablets, Drops). Based on Allergy, the market can be segmented into Allergic rhinitis, Allergic asthma, Others. Based on Distribution Channel, the market can be segmented into Online, Offline (Hospital Pharmacy, Retail Pharmacy). Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Key players in the market are focusing on creating therapies for food allergies in particular by taking advantage of the rising prevalence of allergies. They are funding R&D initiatives in an effort to accomplish the same. To keep ahead of the curve, a number of firms are concentrating on creating new goods, including tablets and injections. 'ALK Abello', 'Allergy Therapeutics', 'Anergis SA', 'ASIT biotech', 'DBV Technologies', 'HAL Allergy Group', 'Hymenoptera Immunotherapy Group', 'Immunomic Therapeutics, Inc.', 'Laboratorios LETI', 'Merck KGaA', 'Novartis International AG', 'Stallergenes Greer plc', 'Tunitas Therapeutics, Inc.', 'VentiRx Pharmaceuticals', 'Biomay AG', 'Genentech, Inc.', 'GlaxoSmithKline plc', 'Meda AB', 'Pfizer Inc.', 'Regeneron Pharmaceuticals, Inc.'

Increasing allergy cases to support the growth of allergy immunotherapy market: The rising prevalence of diverse allergies and the introduction of innovative sublingual immunotherapies in developing nations are the main drivers of market expansion for allergy immunotherapy. In the United States, allergies are the sixth most common chronic illness, costing more than USD 18 billion annually, and affect more than 50 million people, according to data from the American College of Allergy, Asthma & Immunology. Food allergies are becoming more common among both children and adults worldwide. Therefore, it is anticipated that the demand for innovative immunotherapies will be aided by the growing burden of allergic illnesses.

Technology advancements in high-resolution analysis of rare cells in local tissues have led to the emergence of precise and reliable biomarkers for allergy immunotherapy monitoring.

Based on the region, the European region currently dominates the global allergy immunotherapy market with respect to market share, and it is projected that it will continue to hold a sizable share of the market throughout the forecast period. Due to high awareness, increased financing for research and grants, medical reimbursement rules, the rise in the population with allergies, and other factors, Europe was reported to hold the largest share of the worldwide allergy immunotherapy market. According to the European Academy of Allergy and Clinical Immunology (EAACI), 20 percent of the population in the area currently experiences chronic food allergies, which affect over 150 million people.

Feedback From Our Clients

Global Allergy Immunotherapy Market

Product ID: SQSG35I2019